Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study by De Toni, Enrico N. et al.
168  De Toni EN, et al. Gut 2020;69:168–176. doi:10.1136/gutjnl-2018-318193
Hepatology
Original article
Age independent survival benefit for patients with 
hepatocellular carcinoma (HCC) without metastases 
at diagnosis: a population- based study
enrico n De toni   ,1 anne Schlesinger- raab,2 Martin Fuchs,3 Wolfgang Schepp,3 
Ursula ehmer,4 Fabian geisler,4 Jens ricke,5 Philipp Paprottka,6 Helmut Friess,7 
Jens Werner,8 alexander l gerbes,1 Julia Mayerle,1 Jutta engel2
To cite: De toni en, 
Schlesinger- raab a, Fuchs M, 
et al. Gut 2020;69:168–176.
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
gutjnl- 2018- 318193).
For numbered affiliations see 
end of article.
Correspondence to
Dr enrico n De toni, Department 
of internal Medicine 2, 
University of Munich, Muenchen 
80333, germany;  
 enrico. detoni@ med. uni- 
muenchen. de
enDt and aS- r contributed 
equally.
received 28 December 2018
revised 12 February 2019
accepted 21 February 2019
Published Online First 
16 March 2019
© author(s) (or their 
employer(s)) 2020. re- use 
permitted under cc BY- nc. no 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
Significance of this study
What is already known on this subject?
 ► Hepatocellular carcinoma (HCC) is the second 
most common cause of cancer- related death 
worldwide and its incidence is thought to rise 
further on a global scale.
 ► In recent years, several efforts have been 
conducted to improve HCC- mediated mortality: 
these include the development of direct 
antiviral drugs for HCV, the implementation of 
secondary prevention screening programmes, 
the application of algorithms for therapy 
stratification and the improvement of local and 
surgical therapies.
 ► However, whether and to which extent these 
advances have translated into a clinical benefit 
in the general population is a matter of debate.
What are the new findings?
 ► We found that, in contrast to the current 
assumptions, the incidence of HCC over the last 
18 years remained unchanged in Germany.
 ► Furthermore, tumours were diagnosed at a 
progressively earlier stage and median survival 
doubled between 1998 and 2016.
 ► This is due to earlier tumour stage at diagnosis 
independently of the improvement of treatment 
modalities.
 ► To our knowledge, this is the first study 
showing that the advances in the prevention 
and treatment of HCC, well documented in 
clinical studies, translated into a survival 
advantage for HCC patients in the general 
population.
How might it impact on clinical practice in the 
foreseeable future?
 ► Our findings confirm that early diagnosis is 
a major factor influencing survival of HCC 
patients and highlight the need for a consistent 
implementation of surveillance programmes to 
further reduce HCC- related mortality.
AbSTrACT
Objective Hepatocellular carcinoma (Hcc) is a major 
cause of death worldwide and its incidence is expected 
to increase globally. aim of this study was to assess 
whether the implementation of screening policies and 
the improvement of treatment options translated into a 
real- world survival benefit in Hcc patients.
Design 4078 patients diagnosed with Hcc between 
1998 and 2016 from the Munich cancer registry were 
analysed. tumour characteristics and outcome were 
analysed by time period and according to age and 
presence of metastases at diagnosis. Overall survival (OS) 
was analysed using Kaplan- Meier method and relative 
survival (rS) was computed for cancer- specific survival. 
cox proportional hazard models were conducted to 
control for prognostic variables.
results While incidence of Hcc remained substantially 
stable, tumours were diagnosed at increasingly earlier 
stages, although the median age at diagnosis increased. 
the 3 years rS in Hcc improved from 19.8% in 1998–
2002, 22.4% in 2003–2007, 30.6% in 2008–2012 up 
to 31.0% in 2013–2016. Median OS increased from 6 
months in 1998–2002 to 12 months in 2008–2016. 
However, analysis according to the metastatic status 
showed that survival improved only in patients without 
metastases at diagnosis whereas the prognosis of 
patients with metastatic disease remained unchanged.
Conclusion these real- world data show that, in 
contrast to the current assumptions, the incidence of 
Hcc did not increase in a representative german region. 
earlier diagnosis, likely related to the implementation 
of screening programmes, translated into an increasing 
employment of effective therapeutic options and a 
clear survival benefit in patients without metastases at 
diagnosis, irrespective of age.
InTrODuCTIOn
Hepatocellular carcinoma (HCC) is the second 
most common cause of cancer- related death world-
wide, and its incidence is expected to rise further.1 
However, this trend might not reflect the reality of 
single states or regions, due to the different prev-
alence of risk factors, which account for a wide 
variability of incidence.2 In addition, estimations of 
the incidence of HCC could be affected by other 
factors, including the employment of different 
diagnostic criteria and biases influencing reports 
from tertiary care centres, likely reflecting changes 
in referral rates rather than in real incidence.3–5 
In recent years, several efforts have been made 
to improve HCC- related mortality: vaccination 
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Figure 1 Study flowchart.
against HBV is widespread worldwide,6 treatment of chronic 
HCV has considerably improved7 and surveillance programmes 
have been included in international guidelines since the early 
2000s and have been increasingly implemented.8 9
Furthermore, the enactment of therapeutic algorithms and 
the advances in treatment options, including the definition of 
prognosis- based criteria for liver transplantation,10 the more 
recent advent of effective systemic treatment11 and the imple-
mentation of interdisciplinary decision- making processes are 
thought to have contributed to increasing the survival of HCC.12 
However, due to the different availability and accessibility of 
screening programmes and therapeutic options among different 
countries and centres,13 it is not known whether and to which 
extent early diagnosis and the advances in the treatment of HCC 
documented by clinical studies translated into a clinical benefit 
for the general population.14 15
In this study, we aimed at assessing incidence and survival of 
HCC in a German population and the influence of the factors 
determining their change over the last 20 years. To this scope, 
data from a population- based cohort of patients diagnosed with 
HCC between 1998 and 2016 were analysed.
MeTHODS
Data collection
The Munich Cancer Registry (MCR) is a population- based 
clinical cancer registry in Southern Germany comprising the 
region of Upper Bavaria and part of Lower Bavaria. Its catch-
ment area, which comprised 2.3 million inhabitants in 1998, 
was extended to include 3.7 million inhabitants in 2002 and 
4.7 million in 2007. Since then, the population increased to the 
actual 4.8 million inhabitants without further extensions of the 
catchment area. Pathology reports of solid tumours from all 
pathology laboratories in the catchment area are systematically 
sent to the MCR. Additional data are provided by clinicians who 
fill up online standardised forms comprising patients’ residence 
and age, along with other primary disease characteristics such 
as tumour, node, metastases (TNM) stage, histology, grade as 
well as therapies received. The life status of these patients is 
systematically maintained on the basis of death certificates. The 
proportion of patients recorded only owing to the availability of 
a death certificate (death certificate only [DCO] cases) is usually 
high in HCC and averages at 28.3% between 1998 and 2015 
with a tendency to an improving development.16 Data on the age 
distribution of the German population in the last 20 years were 
obtained from the publically available database of the Federal 
Statistical Office (Destatis) and from the Bavarian State Office 
for Statistics.17 18
Patients
Seven thousand three hundred and sixteen patients with resi-
dence in the catchment area were diagnosed between 1998 and 
2016 with liver cancer (figure 1). Patients with intrahepatic 
biliary tumours, sarcoma, lymphoma and fibrolamellar HCC 
were excluded from analysis. After exclusion of 2061 patients 
with DCO, the descriptive analyses comprised 4078 patients 
with HCC. The cohort for survival analyses comprised 3278 
patients with HCC without other past or synchronous malig-
nant diseases.16
Statistics
Data were retrieved from the Oracle database of the MCR; 
statistical analyses were performed by using SAS V.9.4. One- way 
analysis of variance and the chi- square test were used to examine 
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Table 1 Patients and tumour characteristics by period of initial diagnosis (1998–2016, n=4078)
Period of initial diagnosis
1998–2002 2003–2007 2008–2012 2013–2016 Total
P value 
n=623 n=1009 n=1412 n=1034 n=4078
Prognostic factors n (%)* n (%)* n (%)* n (%)* n (%)*
Age (years) 
 Mean±SD 67.1±10.6 68.1±10.4 68.9±10.1 69.1±10.3 68.5±10.3 0.0003
Age in classes (years) 
<50 36 (5.8) 50 (5.0) 52 (3.7) 35 (3.4) 173 (4.2) 0.0006
50–59 102 (16.4) 157 (15.6) 200 (14.2) 164 (15.9) 623 (15.3)
60–69 238 (38.2) 348 (34.5) 450 (31.9) 308 (29.8) 1344 (33.0)
70–79 187 (30.0) 332 (32.9) 537 (38.0) 391 (37.8) 1447 (35.5)
≥80 60 (9.6) 122 (12.1) 173 (12.3) 136 (13.2) 491 (12.0)
Sex 
 Male 476 (76.4) 795 (78.8) 1169 (82.8) 816 (78.9) 3256 (79.8) 0.0038
Female 147 (23.6) 214 (21.2) 243 (17.2) 218 (21.1) 822 (20.2)
c/p T- category† 
 T1 5 (2.2) 99 (34.4) 137 (36.8) 120 (42.3) 361 (31.0) <0.0001
T2 50 (22.1) 55 (19.4) 105 (28.2) 82 (28.9) 292 (25.1)
T3 89 (39.4) 82 (29.0) 95 (25.5) 61 (21.5) 327 (28.1)
T4 74 (32.7) 34 (12.1) 25 (6.7) 17 (6.0) 150 (12.9)
TX 8 (3.5) 13 (4.6) 10 (2.7) 4 (1.4) 35 (3.0)
 Not available 397 (63.7) 726 (72.0) 1040 (73.7) 750 (72.5) 2913 (71.4)
c/p n- category 
 N0 97 (43.5) 131 (50.0) 158 (47.0) 120 (47.8) 506 (47.2) 0.6122 n.s.
N+ 28 (12.6) 32 (12.2) 36 (10.7) 36 (14.3) 132 (12.3)
NX 98 (44.0) 99 (37.8) 142 (42.3) 95 (37.9) 434 (40.5)
 Not available 400 (64.2) 747 (74.0) 1076 (81.1) 783 (75.7) 3006 (73.7)
M- category (primary) 
 M1 80 (12.8) 138 (13.7) 179 (12.7) 113 (10.9) 510 (12.5) 0.2936 n.s.
c/p uICC stage † 
 I 3 (1.4) 45 (16.5) 55 (16.4) 46 (19.3) 149 (14.1) <0.0001
II 20 (9.6) 25 (9.2) 40 (11.9) 26 (10.9) 111 (10.5)
III 42 (20.2) 64 (23.5) 54 (16.1) 30 (12.6) 190 (18.0)
IV 143 (68.8) 138 (50.7) 187 (55.7) 136 (57.1) 604 (57.3
 Not available 415 (66.6) 737 (73.0) 1076 (76.2) 796 (76.9) 3024 (74.2)
Grade 
 G1 89 (26.8) 146 (24.0) 227 (27.5) 164 (27.7) 626 (26.6) 0.0088
G2 155 (46.7) 317 (52.1) 453 (54.8) 312 (52.7) 1237 (52.5)
G3/4 88 (26.5) 145 (23.9) 146 (17.7) 116 (19.6) 495 (21.0)
 Not available 291 (46.7) 401 (39.7) 586 (41.5) 442 (42.7) 1720 (42.2)
*Missing values were excluded from calculations of frequency distribution, column percentage can differ slightly from 100% due to rounding.
†In consequence of a modification of T- category in 2002 many tumours were downstaged (eg, solitary tumours without vascular invasion are classified as T1 irrespective of size).
n.s., Not significant as defined by a level α set at 0.05; UICC ,  Union for International Cancer Control.
continuous variables and the frequency data, respectively. The 
percentages of the presented subcategories were related to the 
sum of each item with available data; missing values were not 
considered. To account for competing risks, a cumulative inci-
dence analysis was used to calculate the time to progression and 
differences among the subgroups were assessed by Gray's test 
for equality of cumulative incidence functions.19 Overall survival 
(OS) was estimated by the Kaplan- Meier method and was 
tested using the log- rank test. Relative survival (RS) was calcu-
lated by the ratio of the observed survival rate to the expected 
survival rate. The expected survival time of age- matched and 
sex- matched individuals was calculated using life tables of the 
general German population using the Ederer II method.20 RS is 
regarded as estimate for cancer- specific survival in cancer registry 
data. The 95% CIs were used to assess significance. Independent 
prognostic factors influencing survival were investigated by Cox 
proportional hazards models. HR and 95% CIs are presented. 
Age, TNM categories and tumour grade were entered simul-
taneously as independent prognostic variables for multivariate 
analyses of survival. Time periods were included as especially 
interesting, independent variables. Groups of missing values of 
each characteristic were included in the Cox models as distinct 
specifications. In order to examine the effects of the time of 
initial diagnosis, four time periods (1998–2002, 2003–2007, 
2008–2012 and 2013–2016) were defined. In parallel to the 
high DCO rate in HCC, there are disproportionately high quotas 
of missing information on tumour and treatment characteris-
tics. For that reason, the time period can represent a surrogate 
parameter for the sum of unknown factors as well as for thera-
peutically progress with potential influence on the outcome of 
HCC patients. To assess the effect of age, the cut- off of 70 years 
was used, because the mean and median age of the analysed 
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Figure 2 (A, B) Analysis of overall survival (OS) according to the Kaplan- Meier method (A) and relative survival (RS) (B) in the whole patients’ 
collective stratified by age group. (C, D) RS by age group in patients without metastasis (M0, C) or with evidence of metastatic disease at initial 
diagnosis (M1, D).
cohort was 68.5 and 69.4 years, respectively. The significance 
level α was set at 0.05 in all statistical tests.
reSulTS
Patient and tumour characteristics
The age- standardised incidences of HCC per year, calculated 
including DCO cases and adjusted for the world standard, 
were 6.4 and 1.5/100 000 in men and women, respectively, 
and remained largely stable throughout the considered period. 
The examined cohort comprises 4078 cases of patients diag-
nosed with HCC between 1998 and 2016 (figure 1) stratified 
by four time periods according to the date of initial diagnosis 
(1998–2002, 2003–2007, 2008–2012, 2013–2016—table 1). 
The increase of absolute numbers of diagnoses in the time period 
2003–2007 and 2008–2012 reflects the enlargement of the 
catchment area in year 2002 and 2007 described in the Method 
section. The average patients’ age increased from 67.1 years in 
the first period to 69.1 years in the last (table 1). As expected, 
the vast majority of HCC patients were male (79.8%) with the 
ratio of male versus female patients further increasing during the 
considered period (p=0.038, table 1). The overall percentage of 
available entries for tumour stage was 28.6% for the primary site 
of tumour (T) and 26.3% for nodal status (N), a proportion that 
did not change during the observation period (p>0.4, data not 
shown). Tumour stage gradually improved over time (T1: from 
34.4% to 42%; T2: from 19.4% to 28.9% between 2003 and 
2016) with a correlative decrease of T3 and T4 stages and a stage- 
shift towards Union for International Cancer Control tumour 
stages I and II. Likewise, the percentage of grade 3–4 tumours 
decreased from 26.5% to 19.6% (table 1).
Diagnostic and treatment modality
Diagnostic liver biopsies decreased steadily from 56% in 2004 
to 30.4% in 2016 (online supplementary table 1). The propor-
tion of surgical or local- ablative treatment conducted in curative 
intention (partial liver resection, liver transplantation and radio- 
frequency ablation [RFA]) increased from 33.4% in 1998–2002 
to 47.2% in 2013–2016. However, also palliative locoregional 
treatment options like transarterial chemoembolisation (TACE) 
and selective internal radiation therapy (SIRT) were performed 
in an increasing fraction of patients (from 17% to 34.5% in the 
same time period). The frequency of systemic chemotherapeutic 
treatment progressively decreased until sorafenib was approved 
in 2008.
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Figure 3 (A, B) Relative survival (RS) according to the Kaplan- Meier method by time period of diagnosis in patients with no metastasis (M0, A) or 
with metastatic disease at diagnosis (M1, B).
Survival
OS and RS rates of the total cohort were 45.5% and 47.2% at 
1 year, 24.5% and 26.5% at 3 years, 16.2 and 18.4 at 5 years, and 
8.2 and 10.4 at 10 years, respectively.
OS and RS stratified by age groups showed only marginal 
differences (figure 2A and B) confirming the poor disease- related 
outcome of HCC and the significant dependency of survival by 
age (p<0.001). Therefore, for all subsequent analyses, only RS 
was presented.
In M0 patients, median survival and 3 years RS rates were 1.8 
years and 40% (95% CI 31.6% to 48.4%) in patients younger 
than 50 years and 7 months and 21% (95% CI 15.2% to 26.6%) 
in patients older than 80 years, respectively (figure 2C). In 
contrast, a median survival of <4 months without age- related 
differences was observed in M1 patients (figure 2D).
Stratification by the time period of diagnosis showed that the 
3 years RS in HCC increased from 19.8% in 1998–2002, 22.4% 
in 2003–2007, 30.6% in 2008–2012 up to 31.0% in 2013–
2016. The median OS increased from 6 months in 1998–2002 
to 12 months in 2008–2016. An improved outcome could be 
observed in M0 patients (figure 3A): median survival increased 
from 7 months in the time period 1998–2002 to 11 months in 
2003–2007 and to 14 months for patients diagnosed in the two 
time periods since 2008, with 3 years RS rates for the respective 
time periods of 22.3% (95% CI 18.4% to 26.2%), 25.5% and 
35% (95% CI 29.4% to 39.6%). In contrast, survival did not 
improve in M1 patients (figure 3B) (with median survival <4 
months) regardless of age at diagnosis (figure 4B).
The time period- dependent improvement of survival in M0 
patients (figures 3A and 4A) was not age dependent and was 
confirmed in the Cox regression analyses which controlled 
for the tumour stage at diagnosis as independent predictor of 
survival (table 2).
DISCuSSIOn
Incidence and age at diagnosis
By assessing the age- adjusted incidence of HCC in our collective, 
we observed a stable incidence of HCC in the last two decades. 
Although our analysis is based on the assessment of data from 
the MCR, we assume that our results are representative of the 
epidemiology of HCC in Germany because the age structure in 
Bavaria is similar to that of the German population.17 18 This 
finding is at odd with the results of studies on the global trend 
of HCC, which consistently show a remarkable increase of the 
incidence of HCC worldwide.21 The discrepancy between the 
stable incidence of HCC observed by us and the increasing 
global trend is most likely due to the comparatively low preva-
lence of chronic HBV and HCV in Germany. Instead, previous 
reports on increasing incidence of HCC in Germany are likely 
attributable to the increasing referral of HCC patients to tertiary 
care centres rather than to variations of incidence in the general 
population.22
Due to the advances in the treatment of HCV, sustained 
virological responses to antiviral treatment have progressively 
increased in recent years and HCV infection has now become a 
virtually curable disease.23 Since HCV affects a disproportionally 
high amount of male patients, it is expected that the increasing 
effectiveness of antiviral treatment will cause a decrease of HCC 
incidence in male patients.24 However, such a trend could not 
be observed in our cohort yet. One possible explanation for this 
might be represented by the latency between HCV infection and 
onset of HCC and the fact that chronic HCV infection remains 
undetected, and thus untreated, in a large proportion of affected 
patients. However, it is also possible that a decline in HCV- 
related HCC is counteracted by a correlative increase of HCC 
related to risk factors known to be increasing in the general 
population, which include non- alcoholic fatty liver disease 
(nonalcoholic steatohepatitis (NASH)), obesity and diabetes.25
The fact that the average age at diagnosis continuously 
increased over the observation period seems to contradict the 
prediction that the observed decrease of tumour stage would be 
accompanied by a decrease of average age at diagnosis. However, 
increasing age at diagnosis may in part reflect the ageing of the 
general population and the progressively improving effective-
ness of treatment for chronic viral hepatitis, possibly resulting in 
a delayed onset of HCC as previously suggested.3
Diagnosis, staging at diagnosis and treatment modality
Since highly specific imaging- based diagnostic criteria for HCC 
were established in the early 2000s, diagnostic biopsy has 
become unnecessary for most patients.26 However, whether 
or not histology should be obtained to confirm the diagnosis 
of HCC or for biomarker- based patients’ stratification, is still 
object of debate.27 In our cohort (online supplementary table 
1), we expectedly observed a clear decline of the frequency of 
biopsies. However, the overall percentage of diagnostic biop-
sies (45%) shows that many physicians still rely on histology for 
diagnosis of HCC.
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Figure 4 (A, B) Relative survival (RS) according to the Kaplan- Meier method by time period at diagnosis in patients younger than 70 years and 
primary non- metastatic disease (M0, A) or with metastasis at diagnosis (M1, B), and in patients aged 70 years or older with non- metastatic (M0, C) or 
metastatic disease (M1, D).
Surveillance by 6- monthly ultrasound examination in at- risk 
patients has been advised since the early 2000. Although 
the actual efficacy of screening programmes has been ques-
tioned,14 15 surveillance for HCC is thought to have contributed 
to the amelioration of the outcome of HCC patients.15 The clear 
shift towards lower stages and lower histological grading at diag-
nosis observed by us supports this notion. In fact, the ameliora-
tion of tumour stage at diagnosis could even be underrated due 
to the well- known stage- migration bias due to improving staging 
procedures.28
Established therapeutic options with curative potential 
comprise ablation techniques like RFA, surgical resection and 
liver transplantation. TACE is used in the palliative setting for 
patients with HCCs confined to the liver. More recently, SIRT 
was employed as alternative to TACE, and since 2008 sorafenib 
has become an effective option for systemic treatment.11 Inter-
estingly, the fraction of liver transplant patients in this cohort has 
not significantly increased compared with resection rates over 
the years. This is specifically interesting in the light of the fact 
that the allocation system has changed during this period of time 
and early HCC has become a privileged indication in the Model 
for End Stage Liver Disease (MELD) system. This may be the 
consequence of lower tumour stage and possibly of better liver 
function at diagnosis allowing for liver resection in an increasing 
fraction of patients. On the other hand, upfront partial hepa-
tectomy might have been increasingly attempted due to the 
increasing organ shortage which represents a limiting factor for 
transplantation. Altogether, the percentage of patients receiving 
a potentially curative treatment or palliative locoregional treat-
ment with established therapeutic relevance increased from 
33.4% to 47.2% and from 17% to 34.5%, respectively, showing 
that lower average tumour stages were associated with a growing 
proportion of patients benefitting from effective treatment 
options.
Survival
Median survival improved considerably, and doubled from 
6 months in 1998–2002 to 12 months in 2008–2012 and 
2013–2016. Cox regression analysis showed that tumour stage 
at diagnosis, tumour grading and the time period of diagnosis 
are independent predictors of survival whereupon time period 
represents a surrogate parameter for therapeutic progress with 
potential influence on the outcome of HCC patients (table 2). 
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Table 2 Cox proportional hazard regression analyses of the association between time period of initial diagnosis and survival according to age and 












Age (years) P<0.0001 * P<0.0001 * P<0.0001 *
<50 Ref. Ref. Ref.
50–59 1.28 (1.03 to 1.58) 1.27 (1.01 to 1.60) 1.39 (0.80 to 2.41)
60–69 1.45 (1.18 to 1.77) 1.43 (1.15 to 1.78) 1.48 (0.88 to 2.48)
70–79 1.73 (1.41 to 2.12) 1.74 (1.39 to 2.17) 1.69 (1.00 to 2.85)
≥80 2.20 (1.76 to 2.75) 2.10 (1.65 to 2.68) 3.08 (1.73 to 5.49)
c/p T category P<0.0001 * P<0.0001 * P=0.1235 *
T1 Ref. Ref. –
T2 1.39 (1.10 to 1.77) 1.41 (1.11 to 1.81) – 
T3 2.37 (1.90 to 2.96) 2.38 (1.89 to 3.00) – 
T4 2.76 (2.11 to 3.60) 2.96 (2.23 to 3.93) – 
T n.a. 2.65 (2.10 to 3.35) 2.79 (2.18 to 3.58) – 
c/p n category P<0.0001 * P<0.0001 *
N0 Ref. Ref. –
N+ 1.70 (1.34 to 2.15) 2.21 (1.65 to 2.94) – 
NX 1.15 (0.97 to 1.36) 1.16 (0.97 to 1.39) – 
N n.a. 1.39 (1.15 to 1.67) 1.38 (1.12 to 1.68) – 
M category P<0.0001 *
M0 Ref. – – 
M1 2.29 (2.05 to 2.56) – – 
Grade P<0.0001 * P<0.0001 * P<0.0001 *
G1 Ref. Ref. Ref.
G2 1.20 (1.05 to 1.36) 1.22 (1.06 to 1.39) 1.02 (0.71 to 1.49)
G3/4 1.72 (1.49 to 2.00) 1.64 (1.40 to 1.93) 2.01 (1.36 to 2.98)
G n.a. 1.39 (1.23 to 1.57) 1.35 (1.19 to 1.54) 1.53 (1.08 to 2.17)
Period of initial diagnosis P<0.0001 * P<0.0001 * P=0.6923 (n.s.) *
1998–2002 Ref. Ref. Ref.
2003–2007 0.92 (0.82 to 1.03) 0.92 (0.81 to 1.04) 1.00 (0.74 to 1.35)
2008–2012 0.73 (0.65 to 0.82) 0.70 (0.62 to 0.79) 1.03 (0.77 to 1.38)
2013–2016 0.64 (0.56 to 0.73) 0.62 (0.54 to 0.72) 0.87 (0.63 to 1.21)














Period of initial diagnosis P<0.0001 * P<0.0001 * P=0.4088 (n.s.) *
1998–2002 Ref. Ref. Ref.
2003–2007 0.95 (0.82 to 1.10) 0.97 (0.83 to 1.15) 0.83 (0.57 to 1.21)
2008–2012 0.71 (0.61 to 0.83) 0.69 (0.58 to 0.81) 0.91 (0.63 to 1.30)
2013–2016 0.63 (0.53 to 0.75) 0.62 (0.51 to 0.76) 0.70 (0.45 to 1.08)














Period of initial diagnosis P<0.0001 * P<0.0001 * P=0.6321 (n.s.) *
1998–2002 Ref. Ref. Ref.
2003–2007 0.88 (0.74 to 1.06) 0.84 (0.69 to 1.02) 1.36 (0.81 to 2.28)
2008–2012 0.74 (0.62 to 0.88) 0.69 (0.57 to 0.83) 1.31 (0.79 to 2.17)
2013–2016 0.64 (0.53 to 0.78) 0.60 (0.49 to 0.75) 1.14 (0.67 to 1.95)
*Wald test.
n.a., Not available; n.s.: not significant as defined by a level α set at 0.05; Ref., reference; TNM, tumour, node, metastases.
The independent significance of tumour staging at diagnosis 
strongly highlights the importance of early diagnosis as deter-
minant of prognosis.29 Importantly, however, the independent 
prognostic significance of the time period of diagnosis suggests 
that availability or improvement of therapeutic strategies 
contributed to the amelioration of survival, as well. This is likely 
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to reflect the enactment of rational treatment algorithms (such as 
the Barcelona Clinic Liver Cancer (BCLC) algorithm, proposed 
in 1999),30 allowing a progressive refinement of patients’ selec-
tion for different therapeutic options, including the introduction 
of the Milan criteria for liver transplantation,10 and restrictions 
to the employment of locoregional strategies.31 Therefore, 
patients not only benefitted from earlier tumour stage at diag-
nosis but also from advances in treatment modalities.32
One interesting finding of our analyses is represented by the 
lack of improvement in survival of patients with primary meta-
static disease (figure 3B). This finding is not entirely unexpected, 
because therapeutic options for patients with advanced disease 
are still very limited.12 Sorafenib, the only evidence- based effec-
tive systemic treatment for HCC available until recently, was 
approved only in 2008; moreover, its employment is limited 
only to a small population of patients with preserved liver 
function despite advanced- stage HCC. Furthermore, its clin-
ical benefit, which amounts to the modest survival advantage of 
about 3 months, is clearly greater in patients without extrahe-
patic disease as shown by subgroup analysis from the Sorafenib 
Hepatocellular Carcinoma Assessment Randomized Protocol 
(SHARP) trial.11 33 These factors explain the lack of improve-
ment in survival of patients with metastatic disease at diagnosis 
and highlight the urgent need for new therapeutic options in this 
patients’ subpopulation.
The increase of survival observed by us is not likely to have 
been the consequence of a lead- time bias, because earlier diag-
nosis was associated with an increasing percentage of patients 
undergoing treatment with well established, potentially creative 
treatment options or with treatment options which are known 
to be associated with a clear benefit in terms of survival and, 
correspondingly, with an improvement of TTP (online supple-
mentary figure 1).15 Correspondingly, no change in the outcome 
of patients with metastatic disease was observed.
limitations
A first limitation of this study is represented by the fact that this, 
being a longitudinal study, might be affected by several biases.
In particular, variables describing liver function are not included 
in our analysis. Such variables are generally not captured by 
cancer registry databases but are important to determine patients’ 
stratification within the BCLC therapeutic algorithm. Therefore, 
we cannot estimate to which extent a possible improvement of 
average liver function in the patients’ population (eg, owing to 
the improvement of antiviral treatments) might have contrib-
uted to improve the prognosis of HCC in recent years. Another 
limitation is given by the high proportion of patients for whom 
only death certificates were available (DCO cases). DCO rates 
for HCC in German cancer registries range between 16% and 
35%.34 35 DCO- related diagnoses are likely to be more frequent 
in patients affected by tumours with more advanced stages at 
diagnosis and with lower life expectancy, and who are thus less 
likely to have received any cancer- specific treatment. Therefore, 
exclusion of DCO patients from analysis of survival might cause 
an overestimation of survival in our collective. Nevertheless, the 
proportion of DCO cases in our study has decreased from 36.5% 
in 1998 to 23.5% in 2015; therefore, the observed improvement 
of survival estimated by time period is more likely to be underes-
timated than overestimated.
Summary
In summary, our results from a multicenter study in Southern 
Germany shows that the incidence of HCC has been stable in 
the last 18 years. Both implementation of screening programmes 
and the advances in the therapeutic stratification are likely to 
have contributed to improve survival of HCC patients in the 
general population. The fact that the prognosis of patients with 
metastatic disease remained unchanged highlights the unmet 
need for effective systemic treatment in patients with advanced 
HCC.
Author affiliations
1Department of Medicine ii, University Hospital, ludwig- Maximilians- University 
(lMU), Munich, germany
2Munich cancer registry, institute for Medical information Processing, Biometry and 
epidemiology, ludwig- Maximilians- University (lMU), Munich, germany
3Department of gastroenterology, Hepatology and gi- Oncology, Hospital 
Bogenhausen, Munich, germany
4Department of internal Medicine ii, Klinikum rechts der isar, technical University of 
Munich (tUM), Munich, germany
5Department of clinical radiology, University Hospital, ludwig- Maximilians- 
University (lMU), Munich, germany
6Department of interventional radiology, Klinikum rechts der isar, technical 
University of Munich (tUM), Munich, germany
7Department of Surgery, Klinikum rechts der isar, School of Medicine, technical 
University of Munich (tUM), Munich, germany
8Department of general, Visceral, Vascular and transplant Surgery, University Hospital, 
ludwig- Maximilians- University (lMU), Munich, germany
Acknowledgements We thank all the hospitals, departments and practitioners 
that participated in the documentation of the data.
Contributors Study concept and design: enDt, aS- r and Je; acquisition of data: 
all authors; analysis and interpretation of data: enDt, aS- r and Je; drafting of 
the manuscript: enDt and aS- r; critical revision of the manuscript for important 
intellectual content: all authors; statistical analysis: enDt, aS- r and Je.
Funding the authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors. 
Competing interests none declared. 
Patient consent for publication not required.
Provenance and peer review not commissioned; externally peer reviewed.
Open access this is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY- nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCID iD
enrico n De toni http:// orcid. org/ 0000- 0002- 8101- 8207
RefeRences
 1 Singal ag, el- Serag HB. Hepatocellular carcinoma from epidemiology to prevention: 
translating knowledge into practice. Clin Gastroenterol Hepatol 2015;13:2140–51.
 2 rich ne, Hester c, Odewole M, et al. racial and ethnic differences in presentation and 
outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551–9.
 3 Weinmann a, Koch S, niederle iM, et al. trends in epidemiology, treatment, and 
survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 
1066 cases of a german Hcc registry. J Clin Gastroenterol 2014;48:279–89.
 4 erhardt a, Zhu e, Blondin D, et al. [increasing number and improved survival of 
patients with hepatocellular carcinoma from 1988 to 2007: data of a german 
university clinic]. Z Gastroenterol 2011;49:720–7.
 5 Schütte K, Kipper M, Kahl S, et al. clinical characteristics and time trends in etiology 
of hepatocellular cancer in germany. Digestion 2013;87:147–59.
 6 liang tJ, Block tM, McMahon BJ, et al. Present and future therapies of hepatitis B: 
From discovery to cure. Hepatology 2015;62:1893–908.
 7 Vermehren J, Park JS, Jacobson iM, et al. challenges and perspectives of direct 
antivirals for the treatment of hepatitis c virus infection. J Hepatol 2018;69:1178–87.
 8 gerbes a, Zoulim F, tilg H, et al. gut roundtable meeting paper: selected recent 
advances in hepatocellular carcinoma. Gut 2018;67:380–8.
 9 Berhane S, toyoda H, tada t, et al. role of the galaD and BalaD-2 Serologic Models 
in Diagnosis of Hepatocellular carcinoma and Prediction of Survival in Patients. Clin 
Gastroenterol Hepatol 2016;14:875–86.
 10 Mazzaferro V, regalia e, Doci r, et al. liver transplantation for the treatment 
of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 
1996;334:693–700.
 on O











176 De toni en, et al. Gut 2020;69:168–176. doi:10.1136/gutjnl-2018-318193
Hepatology
 11 llovet JM, ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular 
carcinoma. N Engl J Med 2008;359:378–90.
 12 european association for the Study of the liver. electronic address: easloffice@
easloffice.eueuropean association for the Study of the liver. eaSl clinical Practice 
guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
 13 Sato M, tateishi r, Yasunaga H, et al. association between hospital volume and in- 
hospital mortality following radiofrequency ablation for hepatocellular carcinoma. BJS 
Open 2017;1:50–4.
 14 Moon aM, Weiss nS, Beste la, et al. no association between screening for 
hepatocellular carcinoma and reduced cancer- related mortality in patients with 
cirrhosis. Gastroenterology 2018;155:1128–39.
 15 cucchetti a, trevisani F, Pecorelli a, et al. estimation of lead- time bias and its impact 
on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J 
Hepatol 2014;61:333–41.
 16 registry Mc. Functions and structure, catchment area, cancer statistics, icD-10 c22 
liver cancer, incidence and mortality. Munich, Bavaria, germany. 2018 https://www. 
tumorregister- muenchen. de/ en/ index. php
 17 Destatis Statistisches Bundesamt. german Population by age- groups. 2019 https://
www. destatis. de/ en/ FactsFigures/ SocietyState/ Population/ currentPopulation/ tables_/ 
lrbev01. html
 18 Bayerisches landesamt für Statistik. Demographisches Profil für den regierungsbezirk 
Oberbayern. 2018 https://www. statistik. bayern. de/ statistik/ byrbz/
 19 Kalbfleisch JD, Prentice rl. The statistical analysis of failure time data. new York: John 
Wiley and Sons, inc, 1980.
 20 ederer F, Heise H. instructions to iBM 650 programmers in processing survival 
computations. Technical, end results evaluation section. Bethesda, MD, USa: national 
cancer institute, 1959.
 21 Bertuccio P, turati F, carioli g, et al. global trends and predictions in hepatocellular 
carcinoma mortality. J Hepatol 2017;67:302–9.
 22 Schurr r, Stölzel U, Schuppan D, et al. [increased incidence of hepatocellular 
and intrahepatic cholangiocellular carcinoma in northeast germany]. Dtsch Med 
Wochenschr 2006;131:1649–55.
 23 Kanwal F, Kramer J, asch SM, et al. risk of Hepatocellular cancer in HcV Patients 
treated With Direct- acting antiviral agents. Gastroenterology 2017;153:996–1005.
 24 Baden r, rockstroh JK, Buti M. natural history and management of hepatitis c: does 
sex play a role? J Infect Dis 2014;209(Suppl 3):S81–5.
 25 estes c, anstee QM, arias- loste Mt, et al. Modeling naFlD disease burden in china, 
France, germany, italy, Japan, Spain, United Kingdom, and United States for the 
period 2016-2030. J Hepatol 2018;69:896–904.
 26 Bruix J, Sherman M, llovet JM, et al. clinical management of hepatocellular 
carcinoma. conclusions of the Barcelona-2000 eaSl conference. european 
association for the Study of the liver. Journal of hepatology 2001;35:421–30.
 27 Mueller c, Waldburger n, Stampfl U, et al. non- invasive diagnosis of hepatocellular 
carcinoma revisited. Gut 2018;67:991–3.
 28 Dinan Ma, curtis lH, carpenter Wr, et al. Stage migration, selection bias, and 
survival associated with the adoption of positron emission tomography among 
medicare beneficiaries with non- small- cell lung cancer, 1998-2003. J Clin Oncol 
2012;30:2725–30.
 29 Simmons Ol, Feng Y, Parikh nD, et al. Primary care Provider Practice Patterns and 
Barriers to Hepatocellular carcinoma Surveillance. Clin Gastroenterol Hepatol 
2019;17.
 30 llovet JM, Brú c, Bruix J. Prognosis of hepatocellular carcinoma: the Bclc staging 
classification. Semin Liver Dis 1999;19:329–38.
 31 White Ja, gray SH, li P, et al. current guidelines for chemoembolization 
for hepatocellular carcinoma: room for improvement? Hepatol Commun 
2017;1:338–46.
 32 Khalaf n, Ying J, Mittal S, et al. natural History of Untreated Hepatocellular carcinoma 
in a US cohort and the role of cancer Surveillance. Clin Gastroenterol Hepatol 
2017;15:273–81.
 33 Bruix J, cheng al, Meinhardt g, et al. Prognostic factors and predictors of sorafenib 
benefit in patients with hepatocellular carcinoma: analysis of two phase iii studies. J 
Hepatol 2017;67:999–1008.
 34 Vohmann c, Urbschat i, Sirri e, et al. Krebs in niedersachsen 2015 [online book 
(pdf)]. Hannover, niedersachen, germany. 2018 www. krebsregister- niedersachsen. de/ 
dateien/ jahresberichte/ jb2015/ eKn% 20Jahresbericht% 202015_ gesamt. pdf.
 35 Krebsregister rheinland- Pfalz. Bericht 2017. leber (c22) Mainz, rheinland- Pfalz, 
germany. 2017 https://www. krebsregister- rlp. de/ veroeffentlichungen/ auswertungen- 
einzelner- krebsarten/ jahr- 2017/ 2017.
 on O






ut: first published as 10.1136/gutjnl-2018-318193 on 16 M
arch 2019. D
ow
nloaded from
 
